ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019)
ENDRA Life Sciences (NDRA) posted quarterly Asset Writedowns and Impairment of $249256.0 for Q4 2019, down 13.31% quarter-over-quarter from $287541.0 in Q3 2018.
ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Asset Writedowns and Impairment for 2 consecutive years, with $249256.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Asset Writedowns and Impairment changed N/A year-over-year to $249256.0; the TTM figure through Dec 2019 stood at $536797.0 (up 86.69% YoY), while the FY2019 annual figure was $249256.0, down 13.31% from the prior year.
- Asset Writedowns and Impairment fell to $249256.0 in Q4 2019 per NDRA's latest filing, from $287541.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $287541.0 in Q3 2018 and bottomed at $249256.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn |
| 10 | ENDRA Life Sciences | 5.44 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 249,256.00 |
| Dec 31, 2019 | 249,256.00 |
| Sep 30, 2018 | 287,541.00 |
| Sep 30, 2018 | 287,541.00 |